Amanta Healthcare IPO to Open on September 1; Price Band Fixed at ₹120-126

New Delhi, August 28, 2025 – Amanta Healthcare Limited will open its book-built IPO from September 1 to September 3, issuing 1 crore new equity shares at ₹120–126. The issue is a completely fresh issue, with an objective of raising ₹126 crore, and allotment is likely on September 4, followed by tentative listing on BSE and NSE around September 8 or 9.

Founded in 1994, Amanta Healthcare Limited is a Gujarat-based sterile liquid pharmaceutical manufacturer specializing in LVPs and SVPs. With a diversified portfolio and global reach, the company now seeks to broaden its capital base through Amanta Healthcare IPO and will be listed on NSE and BSE upon successful completion.

Financial Snapshot & IPO Use of Proceeds

Even as revenue dipped slightly from ₹281.6 crore in FY24 to ₹276.1 crore in FY25-Amanta Healthcare posted a huge 189% PAT growth, reaching ₹10.5 crore, supported by robust EBITDA of ₹61 crore and over 22% margins.

The proceeds of the IPO will be utilised for:

• Commissioning a new SteriPort manufacturing line (~₹70 crore)
• Commissioning a new SVP line (~₹30.13 crore)
• Balance funds for general corporate purposes

Amanta Healthcare’s Strengths

Advanced Manufacturing Infrastructure: A lone, WHO-GMP and ISO-accredited building in Hariyala, Gujarat covering ~66,000 sqm with ABFS and ISBM technology to deliver a broad volume range (2 ml to 1,000 ml)

Diversified Product Range: The company manufactures parenteral products in six therapeutic categories (fluid therapy, diluents, ophthalmic, respiratory, irrigation, etc.) and has 47 products registered in more than 120 foreign jurisdictions

Strong Distribution Network: Underpinned by ~320 distributors and a 96-person sales force in India leveraging digital platforms such as Pharma Cloud for effective distribution and demand planning

Critical Risks to Evaluate

Single-Facility Dependence: All operations focus on a single location; disruption (e.g., natural disaster or licensing problems) would severely impact production and revenues.

Raw Material Vulnerability: Dependence on a finite supplier pool for major inputs such as LDPE and PP granules, which are subject to oil-price volatility.

Historical Compliance & Legal Issues: The firm has had manufacturing licenses suspended in the past, and current legal proceedings may represent an operational or financial threat.

-Currency & Export Exposure: With an export volume contribution of significant proportions (~30-33% of revenue), exchange rate fluctuations or shifts in global demand might affect margins.

REF: https://nsearchives.nseindia.com/content/ipo/RHP_AMANTA.zip

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations